Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ArriVent BioPharma, Inc. Common Stock AVBP NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
58/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$44.00
+59.2%

ArriVent BioPharma, Inc. Common Stock (AVBP) is a Biotechnology company in the Healthcare sector, currently trading at $27.64. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is AVBP = $44 (+59.2% upside).

Valuation: AVBP trades at a trailing Price-to-Earnings (P/E) of -6.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.45.

Net income is $166M (loss), growing at -70.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $14,000 against $307M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 12.83 (strong liquidity). Debt-to-assets is 0%. Total assets: $333M.

Analyst outlook: 6 / 6 analysts rate AVBP as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 91/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$44.00
▲ 59.19% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for ArriVent BioPharma, Inc. Common Stock, the average price target is $44.00, with a high forecast of $45.00, and a low forecast of $43.00.
Highest Price Target
$45.00
Average Price Target
$44.00
Lowest Price Target
$43.00

AVBP SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 91/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AVBP

✓
VALUE Pass
91/100
AVBP trades at a trailing Price-to-Earnings (P/E) of -6.1 (S&P 500 average ~25). Forward PEG 0.45 — Peter Lynch undervalued (≤1.0). Trailing PEG 1.12. Analyst consensus target is $44, implying +59.2% from the current price $28. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
AVBP: +0%/yr revenue is, -70.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet AVBP: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 12.83 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
AVBP: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 6 / 6 analysts rate AVBP as buy (100%). Analyst consensus target is $44 (+59.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range15.47-27.22
Volume329.85K
Avg Volume (30D)518.58K
Market Cap$1.22B
Beta (1Y)0.86
Share Statistics
EPS (TTM)-4.32
Shares Outstanding$38.46M
IPO Date2024-01-26
Employees52
CEOZhengbin Yao
Financial Highlights & Ratios
EBITDA$-177.53M
Net Income$-166.31M
Operating Income$-177.53M
Total Cash$312.82M
Total Debt$14K
Net Debt$-45.53M
Total Assets$333.17M
Price / Earnings (P/E)-6.4
Analyst Forecast
1Y Price Target$44.00
Target High$45.00
Target Low$43.00
Upside+59.2%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS04272N1028

Price Chart

Track all markets on TradingView
AVBP
ArriVent BioPharma, Inc. Common Stock ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
15.47 52WK RANGE 27.22

People Also View

ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.64
+5.20%
 MBX
MBX
MBX Biosciences, Inc. Common Stock
$32.81
-0.03%
 MGTX
MGTX
MeiraGTx Holdings plc
$11.29
+17.24%
 ATXS
ATXS
Astria Therapeutics, Inc.
$12.58
+0.00%
 ARVN
ARVN
Arvinas, Inc.
$11.00
+3.97%
 VALN
VALN
Valneva SE
$6.09
-0.65%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message